Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong
Obesity, Colorectal Cancer, Prostate Cancer
About this trial
This is an interventional screening trial for Obesity focused on measuring Cancer Screening, Colorectal Cancer, Breast Cancer, Prostate Cancer, Obesity, Obesity-related Cancer, Multi-Cancer Screening
Eligibility Criteria
Inclusion Criteria:
- Age 40 to 75 years depending on risk factor(s);
- Measured BMI ≥ 25 kg/m2; or waist circumference >80cm [women] or >90 cm [men]; and
- Absence of existing or previous symptoms suggestive of CRC and breast cancer
Exclusion Criteria:
- Having received updated CRC screening tests (FIT in the past 2 year; flexible sigmoidoscopy in the past 5 years; colonoscopy in the past 10 years);
- Having received updated prostate or breast screening test in the past 2 years;
- Having personal of CRC, prostate or breast cancers;
- Having personal history of colonic adenoma, diverticular disease or inflammatory bowel disease;
- Having medical conditions which were contraindications for colonoscopy, like cardiopulmonary insufficiency and the use of double antiplatelets, etc.; and
- Having medical conditions and disabling conditions with limited life expectancy
Sites / Locations
- Lek Yuen Health CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Colorectal Cancer Screening
Prostate Cancer Screening
Breast Cancer Screening
Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH). This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors.
A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA > 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA < 4 ng/ml or with PHI level < 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).